

Piśmiennictwo

1. Aatola H, Magnussen CG, Koivisto T, et al. Simplified definitions of elevated pediatric blood pressure and high adult arterial stiffness. *Pediatrics*. 2013; 132(1): e70–e76, doi: [10.1542/peds.2012-3426](https://doi.org/10.1542/peds.2012-3426), indexed in Pubmed: [23753088](https://pubmed.ncbi.nlm.nih.gov/23753088/).
2. Abdulsamea S, Anderson P, Biassoni L, et al. Pre- and postcaptopril renal scintigraphy as a screening test for renovascular hypertension in children. *Pediatr Nephrol*. 2010; 25(2): 317–322, doi: [10.1007/s00467-009-1304-9](https://doi.org/10.1007/s00467-009-1304-9), indexed in Pubmed: [19756764](https://pubmed.ncbi.nlm.nih.gov/19756764/).
3. Aboyans V, Ricco JB, Bartelink MLEL, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*. 2018; 39(9): 763–816, doi: [10.1093/eurheartj/ehx095](https://doi.org/10.1093/eurheartj/ehx095), indexed in Pubmed: [28886620](https://pubmed.ncbi.nlm.nih.gov/28886620/).
4. Adelman RD, Coppo R, Dillon MJ. The emergency management of severe hypertension. *Pediatr Nephrol*. 2000; 14(5): 422–427, indexed in Pubmed: [10805473](https://pubmed.ncbi.nlm.nih.gov/10805473/).
5. Afkarian M. Diabetic kidney disease in children and adolescents. *Pediatr Nephrol*. 2015; 30(1): 65–74; quiz 70, doi: [10.1007/s00467-014-2796-5](https://doi.org/10.1007/s00467-014-2796-5), indexed in Pubmed: [24643739](https://pubmed.ncbi.nlm.nih.gov/24643739/).
6. Aggoun Y, Sidi D, Bonnet D. [Arterial dysfunction after treatment of coarctation of the aorta]. *Arch Mal Coeur Vaiss*. 2001; 94(8): 785–789, indexed in Pubmed: [11575204](https://pubmed.ncbi.nlm.nih.gov/11575204/).
7. Alberti KG, Zimmet P, Shaw J, et al. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome — a new worldwide definition. *Lancet*. 2005; 366(9491): 1059–1062, doi: [10.1016/S0140-6736\(05\)67402-8](https://doi.org/10.1016/S0140-6736(05)67402-8), indexed in Pubmed: [16182882](https://pubmed.ncbi.nlm.nih.gov/16182882/).
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA*. 2002; 288(23): 2998–3007, indexed in Pubmed: [12479764](https://pubmed.ncbi.nlm.nih.gov/12479764/).
9. American Diabetes Association. Standards of medical care in diabetes — 2014. *Diabetes Care*. 2014; 37 Suppl 1: S14–S80, doi: [10.2337/dc14-S014](https://doi.org/10.2337/dc14-S014), indexed in Pubmed: [24357209](https://pubmed.ncbi.nlm.nih.gov/24357209/).
10. Anderson WP, Kett MM, Stevenson AJ, et al. Renovascular hypertension. Structural changes in renal vasculature. *Hypertension*. 2000; 36(4): 648–652, indexed in Pubmed: [11040252](https://pubmed.ncbi.nlm.nih.gov/11040252/).
11. Antoniewicz J, Litwin M, Pędich M, et al. Diagnosis and treatment of renovascular hypertension in children and adolescents — single center experience with 87 patients. *J Hypertens*. 2007; 25(Suppl. 2): S332.
12. Antoniewicz J, Litwin M, Pędich M, et al. Diagnosis and treatment of renovascular hypertension in Araki N, Umemura M, Miyagi Y, et al. Expression, transcription, and possible antagonistic interaction of the human Nedd4L gene variant: implications for essential hypertension. *Hypertension*. 2008; 51(3): 773–777, doi: [10.1161/HYPERTENSIONAHA.107.102061](https://doi.org/10.1161/HYPERTENSIONAHA.107.102061), indexed in Pubmed: [18268134](https://pubmed.ncbi.nlm.nih.gov/18268134/).
13. Araki N, Umemura M, Miyagi Y, et al. Expression, transcription, and possible antagonistic interaction of the human Nedd4L gene variant: implications for essential hypertension. *Hypertension*. 2008; 51(3): 773–777, doi: [10.1161/HYPERTENSIONAHA.107.102061](https://doi.org/10.1161/HYPERTENSIONAHA.107.102061), indexed in Pubmed: [18268134](https://pubmed.ncbi.nlm.nih.gov/18268134/).
14. Argente J, Mehls O, Barrios V. Growth and body composition in very young SGA children. *Pediatr Nephrol*. 2010; 25(4): 679–685, doi: [10.1007/s00467-009-1432-2](https://doi.org/10.1007/s00467-009-1432-2), indexed in Pubmed: [20108001](https://pubmed.ncbi.nlm.nih.gov/20108001/).
15. Atanasov AG, Ignatova ID, Nashev LG, et al. Impaired protein stability of 11β-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. *J Am Soc Nephrol*. 2007; 18(4): 1262–1270, doi: [10.1681/ASN.2006111235](https://doi.org/10.1681/ASN.2006111235), indexed in Pubmed: [17314322](https://pubmed.ncbi.nlm.nih.gov/17314322/).
16. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009; 373(9678): 1849–1860, doi: [10.1016/S0140-6736\(09\)60503-1](https://doi.org/10.1016/S0140-6736(09)60503-1), indexed in Pubmed: [19482214](https://pubmed.ncbi.nlm.nih.gov/19482214/).
17. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*. 2004; 292(18): 2227–2236, doi: [10.1001/jama.292.18.2227](https://doi.org/10.1001/jama.292.18.2227), indexed in Pubmed: [15536109](https://pubmed.ncbi.nlm.nih.gov/15536109/).
18. Basiratnia M, Abadi SF, Amirhakimi GH, et al. Ambulatory blood pressure monitoring in children and adolescents with type-1 diabetes mellitus and its relation to diabetic control and microalbuminuria. *Saudi J Kidney Dis Transpl*. 2012; 23(2): 311–315, indexed in Pubmed: [22382225](https://pubmed.ncbi.nlm.nih.gov/22382225/).
19. Baumgartner H, Bonhoeffer P, De Groot NMS, et al. Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC), Association for European Paediatric Cardiology (AEPIC), ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J*. 2010; 31(23): 2915–2957, doi: [10.1093/eurheartj/ehq249](https://doi.org/10.1093/eurheartj/ehq249), indexed in Pubmed: [20801927](https://pubmed.ncbi.nlm.nih.gov/20801927/).
20. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008; 358(18): 1887–1898, doi: [10.1056/NEJMoa0801369](https://doi.org/10.1056/NEJMoa0801369), indexed in Pubmed: [18378519](https://pubmed.ncbi.nlm.nih.gov/18378519/).
21. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (PADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ*. 2008; 337: a1840, doi: [10.1136/bmj.a1840](https://doi.org/10.1136/bmj.a1840), indexed in Pubmed: [18927173](https://pubmed.ncbi.nlm.nih.gov/18927173/).
22. Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. *Hypertension*. 2016; 67(5): 820–825, doi: [10.1161/HYPERTENSIONAHA.115.07020](https://doi.org/10.1161/HYPERTENSIONAHA.115.07020), indexed in Pubmed: [26975708](https://pubmed.ncbi.nlm.nih.gov/26975708/).
23. Bhat MA, Neelakandhan KS, Unnikrishnan M, et al. Fate of hypertension after repair of coarctation of the aorta in adults. *Br J Surg*. 2001; 88(4): 536–538, doi: [10.1046/j.1365-2168.2001.01745.x](https://doi.org/10.1046/j.1365-2168.2001.01745.x), indexed in Pubmed: [11298621](https://pubmed.ncbi.nlm.nih.gov/11298621/).
24. Bhatt DL, Kandzari DE, O'Neill WW, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation

- for resistant hypertension. *N Engl J Med.* 2014; 370(15): 1393–1401, doi: [10.1056/NEJMoa1402670](https://doi.org/10.1056/NEJMoa1402670), indexed in Pubmed: [24678939](https://pubmed.ncbi.nlm.nih.gov/24678939/).
25. Bilginturan N, Zileli S, Karacadağ S, et al. Hereditary brachydactyly associated with hypertension. *J Med Genet.* 1973; 10(3): 253–259, indexed in Pubmed: [4774535](https://pubmed.ncbi.nlm.nih.gov/4774535/).
26. Bloch MJ, Basile JN. Percutaneous revascularization of the renal arteries offers no evidence of clinical benefit in patients with atherosclerotic renal artery stenosis — the ASTRAL trial. *J Clin Hypertens (Greenwich).* 2010; 12(4): 292–294, doi: [10.1111/j.1751-7176.2010.00268.x](https://doi.org/10.1111/j.1751-7176.2010.00268.x), indexed in Pubmed: [20433551](https://pubmed.ncbi.nlm.nih.gov/20433551/).
27. Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med.* 2010; 170(2): 126–135, doi: [10.1001/archinternmed.2009.470](https://doi.org/10.1001/archinternmed.2009.470), indexed in Pubmed: [20101007](https://pubmed.ncbi.nlm.nih.gov/20101007/).
28. Böhm M, Mahfoud F, Ukena C, et al. GSR Investigators. First report of the Global SYMPPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. *Hypertension.* 2015; 65(4): 766–774, doi: [10.1161/HYPERTENSIONAHA.114.05010](https://doi.org/10.1161/HYPERTENSIONAHA.114.05010), indexed in Pubmed: [25691618](https://pubmed.ncbi.nlm.nih.gov/25691618/).
29. Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. *Lancet.* 2017; 389(10085): 2226–2237, doi: [10.1016/S0140-6736\(17\)30754-7](https://doi.org/10.1016/S0140-6736(17)30754-7), indexed in Pubmed: [28390695](https://pubmed.ncbi.nlm.nih.gov/28390695/).
30. Borghi C, Ambrosioni E, Novo S, et al. SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). *Clin Cardiol.* 2012; 35(7): 416–423, doi: [10.1002/clc.22017](https://doi.org/10.1002/clc.22017), indexed in Pubmed: [22707187](https://pubmed.ncbi.nlm.nih.gov/22707187/).
31. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. *Cardiol J.* 2018; 25(5): 545–563, doi: [10.5603/CJ.2018.0116](https://doi.org/10.5603/CJ.2018.0116), indexed in Pubmed: [30394510](https://pubmed.ncbi.nlm.nih.gov/30394510/).
32. Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited — a disorder of sodium reabsorption in the distal tubule. *N Engl J Med.* 1994; 330(3): 178–181, doi: [10.1056/NEJM199401203300305](https://doi.org/10.1056/NEJM199401203300305), indexed in Pubmed: [8264740](https://pubmed.ncbi.nlm.nih.gov/8264740/).
33. Brunström M, Carlberg Bo. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. *JAMA Intern Med.* 2018; 178(1): 28–36, doi: [10.1001/jama-internalmed.2017.6015](https://doi.org/10.1001/jama-internalmed.2017.6015), indexed in Pubmed: [29131895](https://pubmed.ncbi.nlm.nih.gov/29131895/).
34. Brzezinska-Rajszyś G, Qureshi SA, Książek J, et al. Middle aortic syndrome treated by stent implantation. *Heart.* 1999; 81(2): 166–170, doi: [10.1136/hrt.81.2.166](https://doi.org/10.1136/hrt.81.2.166), indexed in Pubmed: [9922353](https://pubmed.ncbi.nlm.nih.gov/9922353/).
35. Buchi KF, Siegler RL. Hypertension in the first month of life. *J Hypertens.* 1986; 4(5): 525–528, indexed in Pubmed: [3794327](https://pubmed.ncbi.nlm.nih.gov/3794327/).
36. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. *Hypertension.* 2012; 60(2): 444–450, doi: [10.1161/HYPERTENSIONAHA.112.196352](https://doi.org/10.1161/HYPERTENSIONAHA.112.196352), indexed in Pubmed: [22753220](https://pubmed.ncbi.nlm.nih.gov/22753220/).
37. Calhoun DA, Jones D, Textor S, et al. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension.* 2008; 51(6): 1403–1419, doi: [10.1161/HYPERTENSIONAHA.108.189141](https://doi.org/10.1161/HYPERTENSIONAHA.108.189141), indexed in Pubmed: [18391085](https://pubmed.ncbi.nlm.nih.gov/18391085/).
38. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. *J Hypertens.* 2006; 24(3): 591–596, doi: [10.1097/01.hjh.0000209993.26057.de](https://doi.org/10.1097/01.hjh.0000209993.26057.de), indexed in Pubmed: [16467663](https://pubmed.ncbi.nlm.nih.gov/16467663/).
39. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. *Hemodial Int.* 2007; 11(1): 21–31, doi: [10.1111/j.1542-4758.2007.00148.x](https://doi.org/10.1111/j.1542-4758.2007.00148.x), indexed in Pubmed: [17257351](https://pubmed.ncbi.nlm.nih.gov/17257351/).
40. Chatterjee M, Speiser PW, Pellizzari M, et al. Poor glycemic control is associated with abnormal changes in 24-hour ambulatory blood pressure in children and adolescents with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab.* 2009; 22(11): 1061–1067, indexed in Pubmed: [20101892](https://pubmed.ncbi.nlm.nih.gov/20101892/).
41. Chaudhuri A, Sutherland SM, Begin B, et al. Role of twenty-four-hour ambulatory blood pressure monitoring in children on dialysis. *Clin J Am Soc Nephrol.* 2011; 6(4): 870–876, doi: [10.2215/CJN.07960910](https://doi.org/10.2215/CJN.07960910), indexed in Pubmed: [21273374](https://pubmed.ncbi.nlm.nih.gov/21273374/).
42. Chavers BM, Solid CA, Daniels FX, et al. Hypertension in pediatric long-term hemodialysis patients in the United States. *Clin J Am Soc Nephrol.* 2009; 4(8): 1363–1369, doi: [10.2215/CJN.01440209](https://doi.org/10.2215/CJN.01440209), indexed in Pubmed: [19556378](https://pubmed.ncbi.nlm.nih.gov/19556378/).
43. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. *Br Med Bull.* 1994; 50(2): 272–298, indexed in Pubmed: [8205459](https://pubmed.ncbi.nlm.nih.gov/8205459/).
44. Constantine E, Linakis J, et al. The assessment and management of hypertensive emergencies and urgencies in children. *Pediatr Emerg Care.* 2005; 21(6): 391–6; quiz 397, indexed in Pubmed: [15942520](https://pubmed.ncbi.nlm.nih.gov/15942520/).
45. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ.* 2007; 334(7599): 885–888, doi: [10.1136/bmj.39147.604896.55](https://doi.org/10.1136/bmj.39147.604896.55), indexed in Pubmed: [17449506](https://pubmed.ncbi.nlm.nih.gov/17449506/).
46. Cosin J, Diez J. TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. *Eur J Heart Fail.* 2002; 4(4): 507–513, indexed in Pubmed: [12167392](https://pubmed.ncbi.nlm.nih.gov/12167392/).
47. Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med.* 2010; 362(17): 1575–1585, doi: [10.1056/NEJMoa1001286](https://doi.org/10.1056/NEJMoa1001286), indexed in Pubmed: [20228401](https://pubmed.ncbi.nlm.nih.gov/20228401/).
48. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002; 359(9311): 995–1003, doi: [10.1016/S0140-6736\(02\)08089-3](https://doi.org/10.1016/S0140-6736(02)08089-3), indexed in Pubmed: [11937178](https://pubmed.ncbi.nlm.nih.gov/11937178/).
49. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised con-

- trolled trial. *Lancet*. 2005; 366(9489): 895–906, doi: [10.1016/S0140-6736\(05\)67185-1](https://doi.org/10.1016/S0140-6736(05)67185-1), indexed in Pubmed: [16154016](https://pubmed.ncbi.nlm.nih.gov/16154016/).
50. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomised controlled trial. *Lancet*. 2005; 366(9489): 895–906, doi: [10.1016/S0140-6736\(05\)67185-1](https://doi.org/10.1016/S0140-6736(05)67185-1), indexed in Pubmed: [16154016](https://pubmed.ncbi.nlm.nih.gov/16154016/).
51. Dallaire F, Slorach C, Hui W, et al. Reference values for pulse wave Doppler and tissue Doppler imaging in pediatric echocardiography. *Circ Cardiovasc Imaging*. 2015; 8(2): e002167, doi: [10.1161/CIRCIMAGING.114.002167](https://doi.org/10.1161/CIRCIMAGING.114.002167), indexed in Pubmed: [25632029](https://pubmed.ncbi.nlm.nih.gov/25632029/).
52. Daniels SR. Repair of coarctation of the aorta and hypertension: does age matter? *Lancet*. 2001; 358(9276): 89–91, doi: [10.1016/S0140-6736\(01\)05378-8](https://doi.org/10.1016/S0140-6736(01)05378-8), indexed in Pubmed: [11463407](https://pubmed.ncbi.nlm.nih.gov/11463407/).
53. de Divitiis M, Pilla C, Kattenhorn M, et al. Ambulatory blood pressure, left ventricular mass, and conduit artery function late after successful repair of coarctation of the aorta. *J Am Coll Cardiol*. 2003; 41(12): 2259–2265, indexed in Pubmed: [12821257](https://pubmed.ncbi.nlm.nih.gov/12821257/).
54. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J Am Coll Cardiol*. 1992; 20(5): 1251–1260, indexed in Pubmed: [1401629](https://pubmed.ncbi.nlm.nih.gov/1401629/).
55. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. *J Am Coll Cardiol*. 1995; 25(5): 1056–1062, indexed in Pubmed: [7897116](https://pubmed.ncbi.nlm.nih.gov/7897116/).
56. de Simone G, Devereux RB, Daniels SR, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J Am Coll Cardiol*. 1992; 20(5): 1251–1260, indexed in Pubmed: [1401629](https://pubmed.ncbi.nlm.nih.gov/1401629/).
57. de Swiet M, Fayers P, Shinebourne EA. Blood pressure survey in a population of newborn infants. *Br Med J*. 1976; 2(6026): 9–11, indexed in Pubmed: [945756](https://pubmed.ncbi.nlm.nih.gov/945756/).
58. de Swiet M, Fayers P, Shinebourne EA. Systolic blood pressure in a population of infants in the first year of life: the Brompton study. *Pediatrics*. 1980; 65(5): 1028–1035, indexed in Pubmed: [7367116](https://pubmed.ncbi.nlm.nih.gov/7367116/).
59. Delaney A, Pellizzari M, Speiser PW, et al. Pitfalls in the measurement of the nocturnal blood pressure dip in adolescents with type 1 diabetes. *Diabetes Care*. 2009; 32(1): 165–168, doi: [10.2337/dc08-1319](https://doi.org/10.2337/dc08-1319), indexed in Pubmed: [18984777](https://pubmed.ncbi.nlm.nih.gov/18984777/).
60. Dereziński T, Kułaga Z, Litwin M. Prevalence of arterial hypertension and anthropometrical predictors of elevated blood pressure in 14 years old adolescents. *Postępy Nauk Medycznych*. 2015; 28(11): 756–759, doi: [10.5604/08606196.1190898](https://doi.org/10.5604/08606196.1190898).
61. Dietel T, Filler G, Grenda R, et al. Bioimpedance and inferior vena cava diameter for assessment of dialysis dry weight. *Pediatr Nephrol*. 2000; 14(10–11): 903–907, indexed in Pubmed: [10975296](https://pubmed.ncbi.nlm.nih.gov/10975296/).
62. Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. *Pediatr Nephrol*. 2012; 27(1): 17–32, doi: [10.1007/s00467-010-1755-z](https://doi.org/10.1007/s00467-010-1755-z), indexed in Pubmed: [21258818](https://pubmed.ncbi.nlm.nih.gov/21258818/).
63. Dodson PM, Lip GY, Eames SM, et al. Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. *J Hum Hypertens*. 1996; 10(2): 93–98, indexed in Pubmed: [8867562](https://pubmed.ncbi.nlm.nih.gov/8867562/).
64. Donaghue KC, Marcovecchio ML, Wadwa RP, et al. International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents. *Pediatr Diabetes*. 2014; 15 Suppl 20: 257–269, doi: [10.1111/pedi.12180](https://doi.org/10.1111/pedi.12180), indexed in Pubmed: [25182318](https://pubmed.ncbi.nlm.nih.gov/25182318/).
65. Doyon A, Kracht D, Bayazit AK, et al. 4C Study Consortium. Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. *Hypertension*. 2013; 62(3): 550–556, doi: [10.1161/HYPERTENSIONAHA.113.01297](https://doi.org/10.1161/HYPERTENSIONAHA.113.01297), indexed in Pubmed: [23817494](https://pubmed.ncbi.nlm.nih.gov/23817494/).
66. Esler MD, Böhm M, Sievert H, et al. Symplicity HTN-2 Investigators, Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet*. 2010; 376(9756): 1903–1909, doi: [10.1016/S0140-6736\(10\)62039-9](https://doi.org/10.1016/S0140-6736(10)62039-9), indexed in Pubmed: [21093036](https://pubmed.ncbi.nlm.nih.gov/21093036/).
67. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016; 387(10022): 957–967, doi: [10.1016/S0140-6736\(15\)01225-8](https://doi.org/10.1016/S0140-6736(15)01225-8), indexed in Pubmed: [26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/).
68. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. *Lancet*. 2002; 360(9343): 1347–1360, doi: [10.1016/S0140-6736\(02\)11403-6](https://doi.org/10.1016/S0140-6736(02)11403-6), indexed in Pubmed: [12423980](https://pubmed.ncbi.nlm.nih.gov/12423980/).
69. Feig DI, Johnson RJ. The role of uric acid in pediatric hypertension. *J Ren Nutr*. 2007; 17(1): 79–83, doi: [10.1053/j.jrn.2006.10.013](https://doi.org/10.1053/j.jrn.2006.10.013), indexed in Pubmed: [17198939](https://pubmed.ncbi.nlm.nih.gov/17198939/).
70. Feig DI, Johnson RJ. The role of uric acid in pediatric hypertension. *J Ren Nutr*. 2007; 17(1): 79–83, doi: [10.1053/j.jrn.2006.10.013](https://doi.org/10.1053/j.jrn.2006.10.013), indexed in Pubmed: [17198939](https://pubmed.ncbi.nlm.nih.gov/17198939/).
71. Feld GF, Waz WR. Pharmacologic therapy of hypertension. In: Feld GF, Waz WR. ed. *Hypertension in children*. Butterworth-Heinemann, Boston 1997: 133–178.
72. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. *Hypertension*. 2009; 53(4): 646–653, doi: [10.1161/HYPERTENSIONAHA.108.123455](https://doi.org/10.1161/HYPERTENSIONAHA.108.123455), indexed in Pubmed: [19237683](https://pubmed.ncbi.nlm.nih.gov/19237683/).
73. Fendler W, Borowiec M, Baranowska-Jazwiecka A, et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. *Diabetologia*. 2012; 55(10): 2631–2635, doi: [10.1007/s00125-012-2621-2](https://doi.org/10.1007/s00125-012-2621-2), indexed in Pubmed: [22782286](https://pubmed.ncbi.nlm.nih.gov/22782286/).
74. Filipovský J, Seidlerová J, Kratochvíl Z, et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. *Blood Press*. 2016; 25(4): 228–234, doi: [10.3109/08037051.2015.1134086](https://doi.org/10.3109/08037051.2015.1134086), indexed in Pubmed: [26852625](https://pubmed.ncbi.nlm.nih.gov/26852625/).
75. Fischer DC, Schreiber C, Heimhalt M, et al. Pediatric reference values of carotid-femoral pulse wave velocity determined with an oscillometric device. *J Hypertens*. 2012; 30(11): 2159–2167, doi: [10.1097/HJH.0b013e3283582217](https://doi.org/10.1097/HJH.0b013e3283582217), indexed in Pubmed: [22940681](https://pubmed.ncbi.nlm.nih.gov/22940681/).
76. Flynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. *Pediatr Nephrol*.

- 2005; 20(7): 961–966, doi: [10.1007/s00467-005-1855-3](https://doi.org/10.1007/s00467-005-1855-3), indexed in Pubmed: [15864653](https://pubmed.ncbi.nlm.nih.gov/15864653/).
77. Flynn JT, Daniels SR, Hayman LL, et al. American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. *Hypertension*. 2014; 63(5): 1116–1135, doi: [10.1161/HYP.0000000000000007](https://doi.org/10.1161/HYP.0000000000000007), indexed in Pubmed: [24591341](https://pubmed.ncbi.nlm.nih.gov/24591341/).
78. Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. *J Pediatr*. 2006; 149(6): 746–754, doi: [10.1016/j.jpeds.2006.08.074](https://doi.org/10.1016/j.jpeds.2006.08.074), indexed in Pubmed: [17137886](https://pubmed.ncbi.nlm.nih.gov/17137886/).
79. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*. 2017; 140(3): e20171904, doi: [10.1542/peds.2017-1904](https://doi.org/10.1542/peds.2017-1904), indexed in Pubmed: [28827377](https://pubmed.ncbi.nlm.nih.gov/28827377/).
80. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. *Pediatr Nephrol*. 2009; 24(6): 1101–1112, doi: [10.1007/s00467-008-1000-1](https://doi.org/10.1007/s00467-008-1000-1), indexed in Pubmed: [18839219](https://pubmed.ncbi.nlm.nih.gov/18839219/).
81. Flynn JT. Neonatal hypertension: diagnosis and management. *Pediatr Nephrol*. 2000; 14(4): 332–341, indexed in Pubmed: [10775081](https://pubmed.ncbi.nlm.nih.gov/10775081/).
82. Friedman AL, Husted VA. Hypertension in babies following discharge from a neonatal intensive care unit. A 3-year follow-up. *Pediatr Nephrol*. 1987; 1(1): 30–34, indexed in Pubmed: [3153257](https://pubmed.ncbi.nlm.nih.gov/3153257/).
83. Funder JW, Carey RM, Fardella C, et al. Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2008; 93(9): 3266–3281, doi: [10.1210/jc.2008-0104](https://doi.org/10.1210/jc.2008-0104), indexed in Pubmed: [18552288](https://pubmed.ncbi.nlm.nih.gov/18552288/).
84. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016; 101(5): 1889–1916, doi: [10.1210/jc.2015-4061](https://doi.org/10.1210/jc.2015-4061), indexed in Pubmed: [26934393](https://pubmed.ncbi.nlm.nih.gov/26934393/).
85. Goldstein DS, Eisenhofer G, Flynn JA, et al. Diagnosis and localization of pheochromocytoma. *Hypertension*. 2004; 43(5): 907–910, doi: [10.1161/01.HYP.0000125014.56023.b8](https://doi.org/10.1161/01.HYP.0000125014.56023.b8), indexed in Pubmed: [15023935](https://pubmed.ncbi.nlm.nih.gov/15023935/).
86. Gornik HL, Persu A, Adlam D, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. *Vasc Med*. 2019; 24(2): 164–189, doi: [10.1177/1358863X18821816](https://doi.org/10.1177/1358863X18821816), indexed in Pubmed: [30648921](https://pubmed.ncbi.nlm.nih.gov/30648921/).
87. Green R, Gu X, Kline-Rogers E, et al. Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US Registry. *Pediatr Nephrol*. 2016; 31(4): 641–650, doi: [10.1007/s00467-015-3234-z](https://doi.org/10.1007/s00467-015-3234-z), indexed in Pubmed: [26525198](https://pubmed.ncbi.nlm.nih.gov/26525198/).
88. Grupa Robocza Polskiego Towarzystwa Naciśnienia Tętniczego. Wytyczne dotyczące diagnostyki i leczenia chorób z guzem chromochłonnym. *Naciśnienie Tętnicze*. 2006; 10(1): 1–19.
89. Grupa Robocza Polskiego Towarzystwa Naciśnienia Tętniczego. Zalecenia dotyczące diagnostyki i leczenia pierwotnego hiperaldosteronizmu. *Naciśnienie Tętnicze*. 2008; 12(3): 155–168.
90. Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. *Am J Hypertens*. 2015; 28(1): 73–80, doi: [10.1093/ajh/hpu083](https://doi.org/10.1093/ajh/hpu083), indexed in Pubmed: [24842390](https://pubmed.ncbi.nlm.nih.gov/24842390/).
91. Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. *Pediatr Nephrol*. 2008; 23(3): 363–371, doi: [10.1007/s00467-007-0643-7](https://doi.org/10.1007/s00467-007-0643-7), indexed in Pubmed: [17990006](https://pubmed.ncbi.nlm.nih.gov/17990006/).
92. Halbach SM, Martz K, Mattoo T, et al. Predictors of blood pressure and its control in pediatric patients receiving dialysis. *J Pediatr*. 2012; 160(4): 621–625.e1, doi: [10.1016/j.jpeds.2011.09.046](https://doi.org/10.1016/j.jpeds.2011.09.046), indexed in Pubmed: [22056352](https://pubmed.ncbi.nlm.nih.gov/22056352/).
93. Haller H, Ito S, Izzo L, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med*. 2011; 364(10): 907–917, doi: [10.1056/NEJMoa1007994](https://doi.org/10.1056/NEJMoa1007994), indexed in Pubmed: [21388309](https://pubmed.ncbi.nlm.nih.gov/21388309/).
94. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*. 1998; 351(9118): 1755–1762, indexed in Pubmed: [9635947](https://pubmed.ncbi.nlm.nih.gov/9635947/).
95. Havekes B, Romijn JA, Eisenhofer G, et al. Update on pediatric pheochromocytoma. *Pediatr Nephrol*. 2009; 24(5): 943–950, doi: [10.1007/s00467-008-0888-9](https://doi.org/10.1007/s00467-008-0888-9), indexed in Pubmed: [18566838](https://pubmed.ncbi.nlm.nih.gov/18566838/).
96. Hoppe A, von Puttkamer C, Linke U, et al. A hospital-based intermittent nocturnal hemodialysis program for children and adolescents. *J Pediatr*. 2011; 158(1): 95–99.e1, doi: [10.1016/j.jpeds.2010.06.036](https://doi.org/10.1016/j.jpeds.2010.06.036), indexed in Pubmed: [20691454](https://pubmed.ncbi.nlm.nih.gov/20691454/).
97. <http://www.dableducational.org>.
98. Inrig JK, Patel UD, Gillespie BS, et al. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. *Am J Kidney Dis*. 2007; 50(1): 108–118.e1, doi: [10.1053/j.ajkd.2007.04.020](https://doi.org/10.1053/j.ajkd.2007.04.020), indexed in Pubmed: [17591530](https://pubmed.ncbi.nlm.nih.gov/17591530/).
99. Jain SR, Smith I, Brewer ED, et al. Non-invasive intravascular monitoring in the pediatric hemodialysis population. *Pediatr Nephrol*. 2001; 16(1): 15–18, indexed in Pubmed: [11198596](https://pubmed.ncbi.nlm.nih.gov/11198596/).
100. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008; 359(23): 2417–2428, doi: [10.1056/NEJMoa0806182](https://doi.org/10.1056/NEJMoa0806182), indexed in Pubmed: [19052124](https://pubmed.ncbi.nlm.nih.gov/19052124/).
101. Jarosz-Chobot P, Polanska J, Szadkowska A, et al. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. *Diabetologia*. 2011; 54(3): 508–515, doi: [10.1007/s00125-010-1993-4](https://doi.org/10.1007/s00125-010-1993-4), indexed in Pubmed: [21165594](https://pubmed.ncbi.nlm.nih.gov/21165594/).
102. Jourdan C, Wühl E, Litwin M, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. *J Hypertens*. 2005; 23(9): 1707–1715, indexed in Pubmed: [16093916](https://pubmed.ncbi.nlm.nih.gov/16093916/).
103. Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. *J Hypertens*. 2006; 24(7): 1397–1403, doi: [10.1097/01.hjh.0000234121.48272.67](https://doi.org/10.1097/01.hjh.0000234121.48272.67), indexed in Pubmed: [16794490](https://pubmed.ncbi.nlm.nih.gov/16794490/).
104. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPPLICITY HTN-3 Trial. *Clin Cardiol*.

- 2012; 35(9): 528–535, doi: [10.1002/clc.22008](https://doi.org/10.1002/clc.22008), indexed in Pubmed: [22573363](https://pubmed.ncbi.nlm.nih.gov/22573363/).
105. Kari JA, Roebuck DJ, McLaren CA, et al. Angioplasty for renovascular hypertension in 78 children. *Arch Dis Child*. 2015; 100(5): 474–478, doi: [10.1136/archdischild-2013-305886](https://doi.org/10.1136/archdischild-2013-305886), indexed in Pubmed: [25527520](https://pubmed.ncbi.nlm.nih.gov/25527520/).
106. Kent AL, Kecskes Z, Shadbolt B, et al. Blood pressure in the first year of life in healthy infants born at term. *Pediatr Nephrol*. 2007; 22(10): 1743–1749, doi: [10.1007/s00467-007-0561-8](https://doi.org/10.1007/s00467-007-0561-8), indexed in Pubmed: [17680275](https://pubmed.ncbi.nlm.nih.gov/17680275/).
107. Kent AL, Kecskes Z, Shadbolt B, et al. Normative blood pressure data in the early neonatal period. *Pediatr Nephrol*. 2007; 22(9): 1335–1341, doi: [10.1007/s00467-007-0480-8](https://doi.org/10.1007/s00467-007-0480-8), indexed in Pubmed: [17437131](https://pubmed.ncbi.nlm.nih.gov/17437131/).
108. Kent AL, Meskell S, Falk MC, et al. Normative blood pressure data in non-ventilated premature neonates from 28–36 weeks gestation. *Pediatr Nephrol*. 2009; 24(1): 141–146, doi: [10.1007/s00467-008-0916-9](https://doi.org/10.1007/s00467-008-0916-9), indexed in Pubmed: [18612658](https://pubmed.ncbi.nlm.nih.gov/18612658/).
109. Khoury PR, Mitsnefes M, Daniels SR, et al. Age-specific reference intervals for indexed left ventricular mass in children. *J Am Soc Echocardiogr*. 2009; 22(6): 709–714, doi: [10.1016/j.echo.2009.03.003](https://doi.org/10.1016/j.echo.2009.03.003), indexed in Pubmed: [19423289](https://pubmed.ncbi.nlm.nih.gov/19423289/).
110. Kit BK, Kuklina E, Carroll MD, et al. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004; 114(2 Suppl 4th Report): 555–576, indexed in Pubmed: [15286277](https://pubmed.ncbi.nlm.nih.gov/15286277/).
111. Kliegman RM, Fanaroff AA. Epidemiology and management of severe symptomatic neonatal hypertension. *Am J Perinatol*. 1986; 3(3): 235–239, doi: [10.1055/s-2007-999874](https://doi.org/10.1055/s-2007-999874), indexed in Pubmed: [3718646](https://pubmed.ncbi.nlm.nih.gov/3718646/).
112. Knerr I, Dost A, Lepler R, et al. Diabetes Data Acquisition System for Prospective Surveillance (DPV) Scientific Initiative Germany and Austria. Tracking and prediction of arterial blood pressure from childhood to young adulthood in 868 patients with type 1 diabetes: a multicenter longitudinal survey in Germany and Austria. *Diabetes Care*. 2008; 31(4): 726–727, doi: [10.2337/dc07-1392](https://doi.org/10.2337/dc07-1392), indexed in Pubmed: [18184906](https://pubmed.ncbi.nlm.nih.gov/18184906/).
113. Kramer AM, van Stralen KJ, Jager KJ, et al. Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. *Kidney Int*. 2011; 80(10): 1092–1098, doi: [10.1038/ki.2011.232](https://doi.org/10.1038/ki.2011.232), indexed in Pubmed: [21814180](https://pubmed.ncbi.nlm.nih.gov/21814180/).
114. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. *Lancet*. 2014; 383(9917): 622–629, doi: [10.1016/S0140-6736\(13\)62192-3](https://doi.org/10.1016/S0140-6736(13)62192-3), indexed in Pubmed: [24210779](https://pubmed.ncbi.nlm.nih.gov/24210779/).
115. Kułaga Z, Litwin M, et al. Zajączkowska M.M. Comparison of waist and hip circumferences ranges in children and adolescents in Poland 7–18 y of age with cardiovascular risk thresholds — initial results of OLAF project (PL0080). *Standardy Medyczne*. 2008; 5: 473–485.
116. Kułaga Z, Litwin M, Grajda A, et al. OLAF Study Group. Oscillometric blood pressure percentiles for Polish normal-weight school-aged children and adolescents. *J Hypertens*. 2012; 30(10): 1942–1954, doi: [10.1097/HJH.0b013e328356abad](https://doi.org/10.1097/HJH.0b013e328356abad), indexed in Pubmed: [22828086](https://pubmed.ncbi.nlm.nih.gov/22828086/).
117. Laakkonen H, Happonen JM, Marttinen E, et al. Normal growth and intravascular volume status with good metabolic control during peritoneal dialysis in infancy. *Pediatr Nephrol*. 2010; 25(8): 1529–1538, doi: [10.1007/s00467-010-1535-9](https://doi.org/10.1007/s00467-010-1535-9), indexed in Pubmed: [20446094](https://pubmed.ncbi.nlm.nih.gov/20446094/).
118. Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. *Pediatr Nephrol*. 2009; 24(10): 1939–1949, doi: [10.1007/s00467-007-0573-4](https://doi.org/10.1007/s00467-007-0573-4), indexed in Pubmed: [17690916](https://pubmed.ncbi.nlm.nih.gov/17690916/).
119. Langbaum M, Eyal FG. A practical and reliable method of measuring blood pressure in the neonate by pulse oximetry. *J Pediatr*. 1994; 125(4): 591–595, indexed in Pubmed: [7931880](https://pubmed.ncbi.nlm.nih.gov/7931880/).
120. Lenders JWM, Duh QY, Eisenhofer G, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014; 99(6): 1915–1942, doi: [10.1210/jc.2014-1498](https://doi.org/10.1210/jc.2014-1498), indexed in Pubmed: [24893135](https://pubmed.ncbi.nlm.nih.gov/24893135/).
121. Levey AS, Rocco MV, Anderson S, et al. K/DOQI Clinical Practice Guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004; 43(5 Suppl 1): S1–S290, indexed in Pubmed: [15114537](https://pubmed.ncbi.nlm.nih.gov/15114537/).
122. Li A, Tedde R, Krozowski ZS, et al. Molecular basis for hypertension in the. *Am J Hum Genet*. 1998; 63(2): 370–379, doi: [10.1086/301955](https://doi.org/10.1086/301955), indexed in Pubmed: [9683587](https://pubmed.ncbi.nlm.nih.gov/9683587/).
123. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012; 380(9859): 2224–2260, doi: [10.1016/S0140-6736\(12\)61766-8](https://doi.org/10.1016/S0140-6736(12)61766-8), indexed in Pubmed: [23245609](https://pubmed.ncbi.nlm.nih.gov/23245609/).
124. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. *J Am Soc Hypertens*. 2008; 2(6): 484–494, doi: [10.1016/j.jash.2008.10.001](https://doi.org/10.1016/j.jash.2008.10.001), indexed in Pubmed: [20409930](https://pubmed.ncbi.nlm.nih.gov/20409930/).
125. Litwin M, Grenda R, Śladowska J, et al. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. *Pediatr Nephrol*. 2006; 21(11): 1716–1722, doi: [10.1007/s00467-006-0223-2](https://doi.org/10.1007/s00467-006-0223-2), indexed in Pubmed: [16909244](https://pubmed.ncbi.nlm.nih.gov/16909244/).
126. Litwin M, Michalkiewicz J, Gackowska L. Primary hypertension in children and adolescents is an immuno-metabolic disease with hemodynamic consequences. *Curr Hypertens Rep*. 2013; 15(4): 331–339, doi: [10.1007/s11906-013-0360-5](https://doi.org/10.1007/s11906-013-0360-5), indexed in Pubmed: [23737217](https://pubmed.ncbi.nlm.nih.gov/23737217/).
127. Litwin M, Niemirska A, Obrycki Ł, et al. Postępowanie diagnostyczne i terapeutyczne w nadciśnieniu tętniczym u dzieci i młodzieży — rekomendacje IPCZD. *Stand Med Pediatr*. 2016; 13: 359–367.
128. Litwin M, Niemirska A, Śladowska J, et al. Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. *Pediatr Nephrol*. 2006; 21(6): 811–819, doi: [10.1007/s00467-006-0068-8](https://doi.org/10.1007/s00467-006-0068-8), indexed in Pubmed: [16565870](https://pubmed.ncbi.nlm.nih.gov/16565870/).
129. Litwin M, Niemirska A, Śladowska-Kozłowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. *Pediatr Nephrol*. 2010; 25(12): 2489–2499, doi: [10.1007/s00467-010-1626-7](https://doi.org/10.1007/s00467-010-1626-7), indexed in Pubmed: [20730452](https://pubmed.ncbi.nlm.nih.gov/20730452/).
130. Litwin M, Niemirska A. Intima-media thickness measurements in children with cardiovascular risk factors. *Pediatr Nephrol*. 2009; 24(4): 707–719, doi: [10.1007/s00467-008-0962-3](https://doi.org/10.1007/s00467-008-0962-3), indexed in Pubmed: [18784945](https://pubmed.ncbi.nlm.nih.gov/18784945/).
131. Litwin M, Śladowska J, Antoniewicz J, et al. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. *Am J Hypertens*. 2007;

- 20(8): 875–882, doi: [10.1016/j.amjhyper.2007.03.005](https://doi.org/10.1016/j.amjhyper.2007.03.005), indexed in Pubmed: [17679036](https://pubmed.ncbi.nlm.nih.gov/17679036/).
132. Litwin M, Sładowska-Kozłowska K. Diagnostyka różnicowa nadciśnienia tętniczego u młodzieży. In: Litwin M, Prejbisz A, Januszewicz A. ed. Nadciśnienie tętnicze u młodzieży i młodych dorosłych. Medycyna Praktyczna, Kraków 2011.
133. Litwin M. Diagnostyka nadciśnienia tętniczego u dzieci. In: Więcek A. ed. Hipertensjologia. Medycyna Praktyczna, Kraków 2010.
134. Litwin M. Leczenie nadciśnienia tętniczego u młodzieży. In: Litwin M, Prejbisz A, Januszewicz A. ed. Nadciśnienie tętnicze u młodzieży i młodych dorosłych. Medycyna Praktyczna, Kraków 2011.
135. Litwin M. Risk factors for renal failure in children with non-glomerular nephropathies. *Pediatr Nephrol.* 2004; 19(2): 178–186, doi: [10.1007/s00467-003-1329-4](https://doi.org/10.1007/s00467-003-1329-4), indexed in Pubmed: [14685838](https://pubmed.ncbi.nlm.nih.gov/14685838/).
136. Litwin M. Risk factors for renal failure in children with non-glomerular nephropathies. *Pediatr Nephrol.* 2004; 19(2): 178–186, doi: [10.1007/s00467-003-1329-4](https://doi.org/10.1007/s00467-003-1329-4), indexed in Pubmed: [14685838](https://pubmed.ncbi.nlm.nih.gov/14685838/).
137. Loeffler LF, Navas-Acien A, Brady TM, et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. *Hypertension.* 2012; 59(4): 811–817, doi: [10.1161/HYPERTENSIONAHA.111.183244](https://doi.org/10.1161/HYPERTENSIONAHA.111.183244), indexed in Pubmed: [22353609](https://pubmed.ncbi.nlm.nih.gov/22353609/).
138. Lonn EM, Bosch J, López-Jaramillo P, et al. HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med.* 2016; 374(21): 2009–2020, doi: [10.1056/NEJMoa1600175](https://doi.org/10.1056/NEJMoa1600175), indexed in Pubmed: [27041480](https://pubmed.ncbi.nlm.nih.gov/27041480/).
139. Low JA, Panagiotopoulos C, Smith JT, et al. Validity of newborn oscillometric blood pressure. *Clin Invest Med.* 1995; 18(3): 163–167, indexed in Pubmed: [7554582](https://pubmed.ncbi.nlm.nih.gov/7554582/).
140. Lucini D, Zuccotti G, Malacarne M, et al. Early progression of the autonomic dysfunction observed in pediatric type 1 diabetes mellitus. *Hypertension.* 2009; 54(5): 987–994, doi: [10.1161/HYPERTENSIONAHA.109.140103](https://doi.org/10.1161/HYPERTENSIONAHA.109.140103), indexed in Pubmed: [19805636](https://pubmed.ncbi.nlm.nih.gov/19805636/).
141. Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens.* 2016; 34(10): 1887–1920, doi: [10.1097/HJH.0000000000001039](https://doi.org/10.1097/HJH.0000000000001039), indexed in Pubmed: [27467768](https://pubmed.ncbi.nlm.nih.gov/27467768/).
142. Lurbe E, Cifkova R, Cruickshank JK, et al. European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. *J Hypertens.* 2009; 27(9): 1719–1742, doi: [10.1097/HJH.0b013e32832f4f6b](https://doi.org/10.1097/HJH.0b013e32832f4f6b), indexed in Pubmed: [19625970](https://pubmed.ncbi.nlm.nih.gov/19625970/).
143. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. *N Engl J Med.* 2002; 347(11): 797–805, doi: [10.1056/NEJMoa013410](https://doi.org/10.1056/NEJMoa013410), indexed in Pubmed: [12226150](https://pubmed.ncbi.nlm.nih.gov/12226150/).
144. Luyckx VA, Perico N, Somaschini M, et al. writing group of the Low Birth Weight and Nephron Number Working Group. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. *Lancet.* 2017; 390(10092): 424–428, doi: [10.1016/S0140-6736\(17\)30576-7](https://doi.org/10.1016/S0140-6736(17)30576-7), indexed in Pubmed: [28284520](https://pubmed.ncbi.nlm.nih.gov/28284520/).
145. Maahs DM, Daniels SR, de Ferranti SD, et al. American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on High Blood Pressure Research, and Council on Lifestyle and Cardiometabolic Health. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. *Circulation.* 2014; 130(17): 1532–1558, doi: [10.1161/CIR.0000000000000094](https://doi.org/10.1161/CIR.0000000000000094), indexed in Pubmed: [25170098](https://pubmed.ncbi.nlm.nih.gov/25170098/).
146. Mahfoud F, Böhm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. *Eur Heart J.* 2015; 36(33): 2219–2227, doi: [10.1093/eurheartj/ehv192](https://doi.org/10.1093/eurheartj/ehv192), indexed in Pubmed: [25990344](https://pubmed.ncbi.nlm.nih.gov/25990344/).
147. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2007; 25(6): 1105–1187, doi: [10.1097/HJH.0b013e3281fc975a](https://doi.org/10.1097/HJH.0b013e3281fc975a), indexed in Pubmed: [17563527](https://pubmed.ncbi.nlm.nih.gov/17563527/).
148. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. *J Hypertens.* 2013; 31: 1281–1357.
149. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens.* 2009; 27(11): 2121–2158, doi: [10.1097/HJH.0b013e328333146d](https://doi.org/10.1097/HJH.0b013e328333146d), indexed in Pubmed: [19838131](https://pubmed.ncbi.nlm.nih.gov/19838131/).
150. Margeisdottir HD, Larsen JR, Brunborg C, et al. Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. *Diabetologia.* 2008; 51(4): 554–561, doi: [10.1007/s00125-007-0921-8](https://doi.org/10.1007/s00125-007-0921-8), indexed in Pubmed: [18196217](https://pubmed.ncbi.nlm.nih.gov/18196217/).
151. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. *J Hypertens.* 2016; 34(8): 1639–1647, doi: [10.1097/HJH.0000000000000977](https://doi.org/10.1097/HJH.0000000000000977), indexed in Pubmed: [27228432](https://pubmed.ncbi.nlm.nih.gov/27228432/).
152. Mayer-Davis EJ, Ma Bo, Lawson A, et al. SEARCH for Diabetes in Youth Study Group. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. *Metab Syndr Relat Disord.* 2009; 7(2): 89–95, doi: [10.1089/met.2008.0046](https://doi.org/10.1089/met.2008.0046), indexed in Pubmed: [18847385](https://pubmed.ncbi.nlm.nih.gov/18847385/).
153. McCambridge TM, Benjamin HJ, Brenner JS, et al. Council on Sports Medicine and Fitness. Athletic participation by children and adolescents who have systemic hypertension. *Pediatrics.* 2010; 125(6): 1287–1294, doi: [10.1542/peds.2010-0658](https://doi.org/10.1542/peds.2010-0658), indexed in Pubmed: [20513738](https://pubmed.ncbi.nlm.nih.gov/20513738/).
154. McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med.* 2010; 362(16): 1477–1490, doi: [10.1056/NEJMoa1001121](https://doi.org/10.1056/NEJMoa1001121), indexed in Pubmed: [20228403](https://pubmed.ncbi.nlm.nih.gov/20228403/).
155. McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med.* 2010; 362(16): 1477–1490, doi: [10.1056/NEJMoa1001121](https://doi.org/10.1056/NEJMoa1001121), indexed in Pubmed: [20228403](https://pubmed.ncbi.nlm.nih.gov/20228403/).
156. Monticone S, Viola A, Rossato D, et al. Adrenal vein sampling in primary aldosteronism: towards a standardised

protocol. *Lancet Diabetes Endocrinol.* 2015; 3(4): 296–303, doi: [10.1016/S2213-8587\(14\)70069-5](https://doi.org/10.1016/S2213-8587(14)70069-5), indexed in Pubmed: [24831990](https://pubmed.ncbi.nlm.nih.gov/24831990/).

157. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr.* 2009; 22(2): 107–133, doi: [10.1016/j.echo.2008.11.023](https://doi.org/10.1016/j.echo.2008.11.023), indexed in Pubmed: [19187853](https://pubmed.ncbi.nlm.nih.gov/19187853/).

158. Nagueh SF, Smiseth OA, Appleton CP, et al. Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr.* 2009; 22(2): 107–133, doi: [10.1016/j.echo.2008.11.023](https://doi.org/10.1016/j.echo.2008.11.023), indexed in Pubmed: [19187853](https://pubmed.ncbi.nlm.nih.gov/19187853/).

159. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics.* 2004; 114(2 Suppl 4th Report): 555–576, doi: [10.1542/peds.114.2.s2.555](https://doi.org/10.1542/peds.114.2.s2.555), indexed in Pubmed: [15286277](https://pubmed.ncbi.nlm.nih.gov/15286277/).

160. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. *Lancet.* 2017; 390(10113): 2627–2642, doi: [10.1016/S0140-6736\(17\)32129-3](https://doi.org/10.1016/S0140-6736(17)32129-3), indexed in Pubmed: [29029897](https://pubmed.ncbi.nlm.nih.gov/29029897/).

161. Niklas A, Flotyńska A, Puch-Walczak A, et al. WOBASZ II investigators. Prevalence, awareness, treatment and control of hypertension in the adult Polish population — Multi-center National Population Health Examination Surveys — WOBASZ studies. *Arch Med Sci.* 2018; 14(5): 951–961, doi: [10.5114/aoms.2017.72423](https://doi.org/10.5114/aoms.2017.72423), indexed in Pubmed: [30154875](https://pubmed.ncbi.nlm.nih.gov/30154875/).

162. Niklas AA, Flotyńska A, Zdrojewski T, et al. Trends in hypertension prevalence, awareness, treatment, and control among Polish adults 75 years and older during 2007–2014. *Cardiol J.* 2018; 25(3): 333–344, doi: [10.5603/CJ.a2018.0043](https://doi.org/10.5603/CJ.a2018.0043), indexed in Pubmed: [29671863](https://pubmed.ncbi.nlm.nih.gov/29671863/).

163. Nwankwo MU, Lorenz JM, Gardiner JC. A standard protocol for blood pressure measurement in the newborn. *Pediatrics.* 1997; 99(6): E10, indexed in Pubmed: [9164806](https://pubmed.ncbi.nlm.nih.gov/9164806/).

164. O'Brien E, Mee F, Atkins N, et al. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Protocol: the Omron HEM-705CP, Phillips HP5332, and Nissei DS-175. *Blood Press Monit.* 1996; 1: 55–61.

165. O'Brien E, Mee F, Atkins N, et al. Short report: Accuracy of the Dinamap portable monitor, model 8100 determined by the British Hypertension Society protocol. *J Hypertens.* 1993; 11(7): 761–763, doi: [10.1097/00004872-199307000-00012](https://doi.org/10.1097/00004872-199307000-00012), indexed in Pubmed: [8228196](https://pubmed.ncbi.nlm.nih.gov/8228196/).

166. Obrycki Ł, Litwin M. Nowe amerykańskie wytyczne postępowania w nadciśnieniu tętniczym u dzieci i młodzieży — najważniejsze zmiany wraz z komentarzem. *Stand Med Pediatr.* 2018; 15: 47–55.

167. Olin JW, Gornik HL, Bacharach JM, et al. American Heart Association Council on Peripheral Vascular Disease, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, American

Heart Association Council on Cardiovascular Disease in the Young, American Heart Association Council on Cardiovascular Radiology and Intervention, American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Functional Genomics and Translational Biology, American Heart Association Council for High Blood Pressure Research, American Heart Association Council on the Kidney in Cardiovascular Disease, American Heart Association Stroke Council. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. *Circulation.* 2014; 129(9): 1048–1078, doi: [10.1161/01.cir.0000442577.96802.8c](https://doi.org/10.1161/01.cir.0000442577.96802.8c), indexed in Pubmed: [24548843](https://pubmed.ncbi.nlm.nih.gov/24548843/).

168. Ortega LM, Materson BJ. Hypertension in peritoneal dialysis patients: epidemiology, pathogenesis, and treatment. *J Am Soc Hypertens.* 2011; 5(3): 128–136, doi: [10.1016/j.jash.2011.02.004](https://doi.org/10.1016/j.jash.2011.02.004), indexed in Pubmed: [21459067](https://pubmed.ncbi.nlm.nih.gov/21459067/).

169. O'Sullivan JJ, Derrick G, Darnell R. Prevalence of hypertension in children after early repair of coarctation of the aorta: a cohort study using casual and 24 hour blood pressure measurement. *Heart.* 2002; 88(2): 163–166, indexed in Pubmed: [12117846](https://pubmed.ncbi.nlm.nih.gov/12117846/).

170. Padwal R, Hemmelgaru BR, Khan NA, et al. The 2008 adian Hypertension Education Program recommendations for the management of hypertension. *Can J Cardiol.* 2008; 24(6): 455–475, indexed in Pubmed: [18548142](https://pubmed.ncbi.nlm.nih.gov/18548142/).

171. Paglialonga F, Ardissino G, Galli MA, et al. Bioimpedance analysis and cardiovascular status in pediatric patients on chronic hemodialysis. *Hemodial Int.* 2012; 16(Suppl 1): S20–S25, doi: [10.1111/j.1542-4758.2012.00743.x](https://doi.org/10.1111/j.1542-4758.2012.00743.x), indexed in Pubmed: [23036032](https://pubmed.ncbi.nlm.nih.gov/23036032/).

172. Parati G, Lombardi C, Hedner J, et al. European Respiratory Society, EU COST ACTION B26 members. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. *J Hypertens.* 2012; 30(4): 633–646, doi: [10.1097/HJH.0b013e328350e53b](https://doi.org/10.1097/HJH.0b013e328350e53b), indexed in Pubmed: [22406463](https://pubmed.ncbi.nlm.nih.gov/22406463/).

173. Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. *J Hypertens.* 2014; 32(7): 1359–1366, doi: [10.1097/HJH.0000000000000221](https://doi.org/10.1097/HJH.0000000000000221), indexed in Pubmed: [24886823](https://pubmed.ncbi.nlm.nih.gov/24886823/).

174. Parati G, Stergiou GS, Asmar R, et al. ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. *J Hypertens.* 2008; 26(8): 1505–1526, doi: [10.1097/HJH.0b013e328308da66](https://doi.org/10.1097/HJH.0b013e328308da66), indexed in Pubmed: [18622223](https://pubmed.ncbi.nlm.nih.gov/18622223/).

175. Park MK, Menard SM. Normative oscillometric blood pressure values in the first 5 years in an office setting. *Am J Dis Child.* 1989; 143(7): 860–864, indexed in Pubmed: [2741863](https://pubmed.ncbi.nlm.nih.gov/2741863/).

176. Park MK, Menard SW, Yuan C. Comparison of auscultatory and oscillometric blood pressures. *Arch Pediatr Adolesc Med.* 2001; 155(1): 50–53, indexed in Pubmed: [11177062](https://pubmed.ncbi.nlm.nih.gov/11177062/).

177. Parving HH, Brenner BM, McMurray JJV, et al. AL-TITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med.* 2012; 367(23):

- 2204–2213, doi: [10.1056/NEJMoa1208799](https://doi.org/10.1056/NEJMoa1208799), indexed in Pubmed: [23121378](https://pubmed.ncbi.nlm.nih.gov/23121378/).
178. Patel A, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007; 370(9590): 829–840, doi: [10.1016/S0140-6736\(07\)61303-8](https://doi.org/10.1016/S0140-6736(07)61303-8), indexed in Pubmed: [17765963](https://pubmed.ncbi.nlm.nih.gov/17765963/).
179. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)*. 1995; 108(9): 710–717, indexed in Pubmed: [8575241](https://pubmed.ncbi.nlm.nih.gov/8575241/).
180. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA*. 2003; 290(21): 2805–2816, doi: [10.1001/jama.290.21.2805](https://doi.org/10.1001/jama.290.21.2805), indexed in Pubmed: [14657064](https://pubmed.ncbi.nlm.nih.gov/14657064/).
181. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2012; 33(13): 1635–1701, doi: [10.1093/eurheartj/ehs092](https://doi.org/10.1093/eurheartj/ehs092), indexed in Pubmed: [22555213](https://pubmed.ncbi.nlm.nih.gov/22555213/).
182. Persu A, Giavarini A, Touzé E, et al. ESH Working Group Hypertension and the Kidney. European consensus on the diagnosis and management of fibromuscular dysplasia. *J Hypertens*. 2014; 32(7): 1367–1378, doi: [10.1097/HJH.0000000000000213](https://doi.org/10.1097/HJH.0000000000000213), indexed in Pubmed: [24842696](https://pubmed.ncbi.nlm.nih.gov/24842696/).
183. Peterson AL, Frommelt PC, Mussatto K. Presentation and echocardiographic markers of neonatal hypertensive cardiomyopathy. *Pediatrics*. 2006; 118(3): e782–e785, doi: [10.1542/peds.2006-0631](https://doi.org/10.1542/peds.2006-0631), indexed in Pubmed: [16880252](https://pubmed.ncbi.nlm.nih.gov/16880252/).
184. Pęczkowska M, Januszewicz A, Jarzab B, et al. Pheochromocytoma in children and adolescents based on Polish Pheochromocytoma Registry. *Ann Diag Paed Pathol*. 2007; 11: 15–19.
185. Pietrzak I, Mianowska B, Gadzicka A, et al. Blood pressure in children and adolescents with type 1 diabetes mellitus — the influence of body mass index and fat mass. *Pediatr Endocrinol Diabetes Metab*. 2009; 15(4): 240–245, indexed in Pubmed: [20455418](https://pubmed.ncbi.nlm.nih.gov/20455418/).
186. Pływaczewski R, Brzecka A, Bielicki P, et al. Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia zaburzeń oddychania w czasie snu (ZOCS) u dorosłych. *Pneumonol Alergol Pol*. 2013; 81: 221–258.
187. Prejbisz A, Warchoł-Celińska E, Lenders JWM, et al. Cardiovascular Risk in Primary Hyperaldosteronism. *Horm Metab Res*. 2015; 47(13): 973–980, doi: [10.1055/s-0035-1565124](https://doi.org/10.1055/s-0035-1565124), indexed in Pubmed: [26575306](https://pubmed.ncbi.nlm.nih.gov/26575306/).
188. Qaseem A, Holty JEC, Owens DK, et al. Clinical Guidelines Committee of the American College of Physicians. Management of obstructive sleep apnea in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2013; 159(7): 471–483, doi: [10.7326/0003-4819-159-7-201310010-00704](https://doi.org/10.7326/0003-4819-159-7-201310010-00704), indexed in Pubmed: [24061345](https://pubmed.ncbi.nlm.nih.gov/24061345/).
189. Report of the Second Task Force on Blood Pressure Control in Children—1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. *Pediatrics*. 1987; 79(1): 1–25, indexed in Pubmed: [3797155](https://pubmed.ncbi.nlm.nih.gov/3797155/).
190. Reusz GS, Csepkekal O, Temmar M, et al. Reference values of pulse wave velocity in healthy children and teenagers. *Hypertension*. 2010; 56(2): 217–224, doi: [10.1161/HYPERTENSIONAHA.110.152686](https://doi.org/10.1161/HYPERTENSIONAHA.110.152686), indexed in Pubmed: [20566959](https://pubmed.ncbi.nlm.nih.gov/20566959/).
191. Ridker PM, Danielson E, Fonseca FA, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008; 359: 2195–2207, doi: [10.1056/NEJMoa0807646](https://doi.org/10.1056/NEJMoa0807646), indexed in Pubmed: [18997196](https://pubmed.ncbi.nlm.nih.gov/18997196/).
192. Rodriguez BL, Dabelea D, Liese AD, et al. SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. *J Pediatr*. 2010; 157(2): 245–251.e1, doi: [10.1016/j.jpeds.2010.02.021](https://doi.org/10.1016/j.jpeds.2010.02.021), indexed in Pubmed: [20394942](https://pubmed.ncbi.nlm.nih.gov/20394942/).
193. Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. *Hypertension*. 2014; 63(1): 151–160, doi: [10.1161/HYPERTENSIONAHA.113.02097](https://doi.org/10.1161/HYPERTENSIONAHA.113.02097), indexed in Pubmed: [24218436](https://pubmed.ncbi.nlm.nih.gov/24218436/).
194. Rozporządzenie Ministra Zdrowia z dnia 29 sierpnia 2009 r. w sprawie świadczeń gwarantowanych z zakresu podstawowej opieki zdrowotnej. *Dz.U.* 2009; 139: 1139.
195. Saito Y, Okada S, Ogawa H, et al. JPAD Trial Investigators. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. *Thromb Haemost*. 2010; 104(6): 1085–1088, doi: [10.1160/TH10-05-0333](https://doi.org/10.1160/TH10-05-0333), indexed in Pubmed: [20941462](https://pubmed.ncbi.nlm.nih.gov/20941462/).
196. Salardi S, Balsamo C, Zucchini S, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. *Diabetes Care*. 2011; 34(2): 424–429, doi: [10.2337/dc10-1177](https://doi.org/10.2337/dc10-1177), indexed in Pubmed: [21216861](https://pubmed.ncbi.nlm.nih.gov/21216861/).
197. Schrader J, Lüders S, Kulschewski A, et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). *Stroke*. 2005; 36(6): 1218–1226, doi: [10.1161/01.STR.0000166048.35740.a9](https://doi.org/10.1161/01.STR.0000166048.35740.a9), indexed in Pubmed: [15879332](https://pubmed.ncbi.nlm.nih.gov/15879332/).
198. Shasha SM, Ben Dror G, Epstein L, et al. Report of the Second Task Force on Blood Pressure Control in Children — 1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. *Pediatrics*. 1987; 79(1): 1–25, indexed in Pubmed: [3797155](https://pubmed.ncbi.nlm.nih.gov/3797155/).
199. Shroff R, Roebuck DJ, Gordon I, et al. Angioplasty for renovascular hypertension in children: 20-year experience. *Pediatrics*. 2006; 118(1): 268–275, doi: [10.1542/peds.2005-2642](https://doi.org/10.1542/peds.2005-2642), indexed in Pubmed: [16818574](https://pubmed.ncbi.nlm.nih.gov/16818574/).
200. Singh HP, Hurley RM, Myers TF. Neonatal hypertension. Incidence and risk factors. *Am J Hypertens*. 1992; 5(2): 51–55, indexed in Pubmed: [1550665](https://pubmed.ncbi.nlm.nih.gov/1550665/).
201. Skalina ME, Kliegman RM, Fanaroff AA. Epidemiology and management of severe symptomatic neonatal hypertension. *Am J Perinatol*. 1986; 3(3): 235–239, doi: [10.1055/s-2007-999874](https://doi.org/10.1055/s-2007-999874), indexed in Pubmed: [3718646](https://pubmed.ncbi.nlm.nih.gov/3718646/).
202. Sładowska J, Niemirska A, Litwin M, et al. Naciśnienie tętnicze u dzieci. Część 1: Zasady postępowania diagnostycznego. *Standardy Med*. 2005; 2: 1452–1462.
203. Slovut DP, Olin JW. Fibromuscular dysplasia. *N Engl J Med*. 2004; 350(18): 1862–1871, doi: [10.1056/NEJMra032393](https://doi.org/10.1056/NEJMra032393), indexed in Pubmed: [15115832](https://pubmed.ncbi.nlm.nih.gov/15115832/).

204. Soejima H, Morimoto T, Saito Y, et al. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. *Thromb Haemost*. 2010; 104(6): 1085–1088, doi: [10.1160/TH10-05-0333](https://doi.org/10.1160/TH10-05-0333), indexed in Pubmed: [20941462](https://pubmed.ncbi.nlm.nih.gov/20941462/).
205. Springer SC, Silverstein J, Copeland K, et al. American Academy of Pediatrics. Management of type 2 diabetes mellitus in children and adolescents. *Pediatrics*. 2013; 131(2): e648–e664, doi: [10.1542/peds.2012-3496](https://doi.org/10.1542/peds.2012-3496), indexed in Pubmed: [23359584](https://pubmed.ncbi.nlm.nih.gov/23359584/).
206. Staessen JA, Thijsq L, Fagard R, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. *J Hypertens*. 2004; 22(4): 847–857, indexed in Pubmed: [15126928](https://pubmed.ncbi.nlm.nih.gov/15126928/).
207. Standardy opieki ambulatoryjnej nad dzieckiem urodzonym przedwcześnie. Zalecenia Polskiego Towarzystwa Neonatologicznego i Polskiego Towarzystwa Pediatrycznego. Media-Press, Warszawa 2017.
208. Stanowisko grupy ekspertów dotyczące diagnostyki obrazowej i wskazań do wykonywania zabiegów przezskórnej angioplastyki zwężenia tętnicy nerkowej u chorych z NT. Przyjęte przez Polskie Towarzystwo Nadciśnienia Tętniczego, Polskie Towarzystwo Nefrologiczne i Polskie Towarzystwo Kardiologiczne. *Kardiologia Polska*. 2010; 68(7): 860–867.
209. Stanowisko PTNT. Stosowanie produktów o ograniczonej zawartości sodu. *Nadciśnienie Tętnicze*. 2007; 11(1): 84.
210. Stergiou GS, Christodoulakis G, Giovos P, et al. Home blood pressure monitoring in children: how many measurements are needed? *Am J Hypertens*. 2008; 21(6): 633–638, doi: [10.1038/ajh.2008.38](https://doi.org/10.1038/ajh.2008.38), indexed in Pubmed: [18443574](https://pubmed.ncbi.nlm.nih.gov/18443574/).
211. Stewart P. Dexamethasone-suppressible hypertension. *Lancet*. 2000; 356(9231): 697–699, doi: [10.1016/s0140-6736\(00\)02624-6](https://doi.org/10.1016/s0140-6736(00)02624-6), indexed in Pubmed: [11085685](https://pubmed.ncbi.nlm.nih.gov/11085685/).
212. Suláková T, Janda J, Cerná J, et al. Arterial hypertension in children with type 1 diabetes mellitus: frequent and not easy to diagnose. *Pediatr Diabetes*. 2009; 10(7): 441–448, doi: [10.1111/j.1399-5448.2009.00514.x](https://doi.org/10.1111/j.1399-5448.2009.00514.x), indexed in Pubmed: [19500279](https://pubmed.ncbi.nlm.nih.gov/19500279/).
213. Symonides B, Jędrusik P, Artyszuk L, et al. Different diagnostic criteria significantly affect the rates of hypertension in 18-year-old high school students. *Arch Med Sci*. 2010; 6(5): 689–694, doi: [10.5114/aoms.2010.17082](https://doi.org/10.5114/aoms.2010.17082), indexed in Pubmed: [22419926](https://pubmed.ncbi.nlm.nih.gov/22419926/).
214. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. *Hypertension*. 2011; 57(5): 911–917, doi: [10.1161/HYPERTENSIONA-HA.110.163014](https://doi.org/10.1161/HYPERTENSIONA-HA.110.163014), indexed in Pubmed: [21403086](https://pubmed.ncbi.nlm.nih.gov/21403086/).
215. Szymański FM, Barylski M, Cybulska B, et al. Recommendation for the management of dyslipidemia in Poland — Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. *Cardiol J*. 2018; 25(6): 655–665, doi: [10.5603/CJ.2018.0141](https://doi.org/10.5603/CJ.2018.0141), indexed in Pubmed: [30600830](https://pubmed.ncbi.nlm.nih.gov/30600830/).
216. Tan BK, Chan C, Davies SJ. Achieving euolemia in peritoneal dialysis patients: a surprisingly difficult proposition. *Semin Dial*. 2010; 23(5): 456–461, doi: [10.1111/j.1525-139X.2010.00739.x](https://doi.org/10.1111/j.1525-139X.2010.00739.x), indexed in Pubmed: [21039874](https://pubmed.ncbi.nlm.nih.gov/21039874/).
217. Tendera M, Aboyans V, Bartelink ML, et al. European Stroke Organisation, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. 2011; 32(22): 2851–2906, doi: [10.1093/eurheartj/ehr211](https://doi.org/10.1093/eurheartj/ehr211), indexed in Pubmed: [21873417](https://pubmed.ncbi.nlm.nih.gov/21873417/).
218. Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant*. 2012; 27(11): 4180–4188, doi: [10.1093/ndt/gfs021](https://doi.org/10.1093/ndt/gfs021), indexed in Pubmed: [22431708](https://pubmed.ncbi.nlm.nih.gov/22431708/).
219. Thomopoulos C, Parati G, Zanchetti A, et al. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. *J Hypertens*. 2014; 32(12): 2285–2295, doi: [10.1097/HJH.0000000000000378](https://doi.org/10.1097/HJH.0000000000000378), indexed in Pubmed: [25255397](https://pubmed.ncbi.nlm.nih.gov/25255397/).
220. Tkaczyk M, Nowicki M, Bałasz-Chmielewska I, et al. Hypertension in dialysed children: the prevalence and therapeutic approach in Poland — a nationwide survey. *Nephrol Dial Transplant*. 2006; 21(3): 736–742, doi: [10.1093/ndt/gfi280](https://doi.org/10.1093/ndt/gfi280), indexed in Pubmed: [16303782](https://pubmed.ncbi.nlm.nih.gov/16303782/).
221. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care*. 2013; 36(6): 1758–1764, doi: [10.2337/dc12-2388](https://doi.org/10.2337/dc12-2388), indexed in Pubmed: [23704675](https://pubmed.ncbi.nlm.nih.gov/23704675/).
222. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care*. 2013; 36(6): 1735–1741, doi: [10.2337/dc12-2420](https://doi.org/10.2337/dc12-2420), indexed in Pubmed: [23704672](https://pubmed.ncbi.nlm.nih.gov/23704672/).
223. Toka O, Maass PG, Aydin A, et al. Childhood hypertension in autosomal-dominant hypertension with brachydactyly. *Hypertension*. 2010; 56(5): 988–994, doi: [10.1161/HYPERTENSIONA-HA.110.156620](https://doi.org/10.1161/HYPERTENSIONA-HA.110.156620), indexed in Pubmed: [20837885](https://pubmed.ncbi.nlm.nih.gov/20837885/).
224. Tołwińska J, Głowińska-Olszewska B, Bossowski A. Insulin therapy with personal insulin pumps and early angiopathy in children with type 1 diabetes mellitus. *Mediators Inflamm*. 2013; 2013: 791283, doi: [10.1155/2013/791283](https://doi.org/10.1155/2013/791283), indexed in Pubmed: [24347835](https://pubmed.ncbi.nlm.nih.gov/24347835/).
225. Townsend RR, Mahfoud F, Kandzari DE, et al. SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet*. 2017; 390(10108): 2160–2170, doi: [10.1016/S0140-6736\(17\)32281-X](https://doi.org/10.1016/S0140-6736(17)32281-X), indexed in Pubmed: [28859944](https://pubmed.ncbi.nlm.nih.gov/28859944/).
226. Trautmann A, Roebuck DJ, McLaren CA, et al. Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. *Pediatr Nephrol*. 2017; 32(3): 495–502, doi: [10.1007/s00467-016-3501-7](https://doi.org/10.1007/s00467-016-3501-7), indexed in Pubmed: [27747454](https://pubmed.ncbi.nlm.nih.gov/27747454/).
227. Turnbull F, Neal B, Ninomiya T, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ*. 2008; 336(7653): 1121–1123, doi: [10.1136/bmj.39548.738368.BE](https://doi.org/10.1136/bmj.39548.738368.BE), indexed in Pubmed: [18480116](https://pubmed.ncbi.nlm.nih.gov/18480116/).
228. Turnbull F, Woodward M, Neal B, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.

- Eur Heart J. 2008; 29(21): 2669–2680, doi: [10.1093/eurheartj/ehn427](https://doi.org/10.1093/eurheartj/ehn427), indexed in Pubmed: [18852183](https://pubmed.ncbi.nlm.nih.gov/18852183/).
229. Tykarski A, Narkiewicz K, Gaciong Z. Zasady postępowania w nadciśnieniu tętniczym — 2015 rok. *Nadciśnienie Tętnicze w Praktyce*. 2015; 1: 1–70.
230. Tykarski A, Widecka K, Narkiewicz K, et al. Leki złożone w terapii nadciśnienia tętniczego w Polsce. Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. *Arterial Hypertension*. 2017; 21(3): 105–115, doi: [10.5603/ah.2017.0014](https://doi.org/10.5603/ah.2017.0014).
231. Urbina E, Alpert B, Flynn J, et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. *Hypertension*. 2008; 52(3): 433–451, doi: [10.1161/HYPERTENSIONAHA.108.190329](https://doi.org/10.1161/HYPERTENSIONAHA.108.190329), indexed in Pubmed: [18678786](https://pubmed.ncbi.nlm.nih.gov/18678786/).
232. Van Bortel LM, Laurent S, Boutouyrie P, et al. Artery Society, European Society of Hypertension Working Group on Vascular Structure and Function, European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012; 30(3): 445–448, doi: [10.1097/HJH.0b013e32834fa8b0](https://doi.org/10.1097/HJH.0b013e32834fa8b0), indexed in Pubmed: [22278144](https://pubmed.ncbi.nlm.nih.gov/22278144/).
233. Vehaskari VM. Heritable forms of hypertension. *Pediatr Nephrol*. 2009; 24(10): 1929–1937, doi: [10.1007/s00467-007-0537-8](https://doi.org/10.1007/s00467-007-0537-8), indexed in Pubmed: [17647025](https://pubmed.ncbi.nlm.nih.gov/17647025/).
234. Verdecchia P, Staessen JA, Angeli F, et al. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet*. 2009; 374(9689): 525–533, doi: [10.1016/S0140-6736\(09\)61340-4](https://doi.org/10.1016/S0140-6736(09)61340-4), indexed in Pubmed: [19683638](https://pubmed.ncbi.nlm.nih.gov/19683638/).
235. Vuguin PM. Animal models for small for gestational age and fetal programming of adult disease. *Horm Res*. 2007; 68(3): 113–123, doi: [10.1159/000100545](https://doi.org/10.1159/000100545), indexed in Pubmed: [17351325](https://pubmed.ncbi.nlm.nih.gov/17351325/).
236. Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis and treatment of pediatric pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab*. 2010; 95(5): 2023–2037, doi: [10.1210/jc.2009-2830](https://doi.org/10.1210/jc.2009-2830), indexed in Pubmed: [20215394](https://pubmed.ncbi.nlm.nih.gov/20215394/).
237. Watkinson M. Hypertension in the newborn baby. *Arch Dis Child Fetal Neonatal Ed*. 2002; 86(2): F78–F81, indexed in Pubmed: [11882547](https://pubmed.ncbi.nlm.nih.gov/11882547/).
238. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. *Lancet*. 2004; 363(9426): 2049–2051, doi: [10.1016/S0140-6736\(04\)16456-8](https://doi.org/10.1016/S0140-6736(04)16456-8), indexed in Pubmed: [15207957](https://pubmed.ncbi.nlm.nih.gov/15207957/).
239. Whelton PK, Carey RM, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018; 71(19): e127–e248, doi: [10.1016/j.jacc.2017.11.006](https://doi.org/10.1016/j.jacc.2017.11.006), indexed in Pubmed: [29146535](https://pubmed.ncbi.nlm.nih.gov/29146535/).
240. Williams B, MacDonald TM, Morant SV, et al. British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. *Lancet Diabetes Endocrinol*. 2018; 6(6): 464–475, doi: [10.1016/S2213-8587\(18\)30071-8](https://doi.org/10.1016/S2213-8587(18)30071-8), indexed in Pubmed: [29655877](https://pubmed.ncbi.nlm.nih.gov/29655877/).
241. Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018; 39(33): 3021–3104, doi: [10.1093/eurheartj/ehy339](https://doi.org/10.1093/eurheartj/ehy339), indexed in Pubmed: [30165516](https://pubmed.ncbi.nlm.nih.gov/30165516/).
242. Witkowski A, Januszewicz A, Imiela J, et al. Stanowisko grupy ekspertów w sprawie zabiegów przezskórnej denerwacji nerek w leczeniu nadciśnienia tętniczego w Polsce. *Kardiol Pol*. 2011; 69(11): 1208–1211.
243. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. *Hypertension*. 2011; 58(4): 559–565, doi: [10.1161/HYPERTENSIONAHA.111.173799](https://doi.org/10.1161/HYPERTENSIONAHA.111.173799), indexed in Pubmed: [21844482](https://pubmed.ncbi.nlm.nih.gov/21844482/).
244. Wong H, Mylrea K, Feber J, et al. Prevalence of complications in children with chronic kidney disease according to KDOQI. *Kidney Int*. 2006; 70(3): 585–590, doi: [10.1038/sj.ki.5001608](https://doi.org/10.1038/sj.ki.5001608), indexed in Pubmed: [16788689](https://pubmed.ncbi.nlm.nih.gov/16788689/).
245. Wong TY, Mitchell P. Hypertensive retinopathy. *N Engl J Med*. 2004; 351(22): 2310–2317, doi: [10.1056/NEJMra032865](https://doi.org/10.1056/NEJMra032865), indexed in Pubmed: [15564546](https://pubmed.ncbi.nlm.nih.gov/15564546/).
246. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015; 373(22): 2103–2116, doi: [10.1056/NEJMoa1511939](https://doi.org/10.1056/NEJMoa1511939), indexed in Pubmed: [26551272](https://pubmed.ncbi.nlm.nih.gov/26551272/).
247. Wühl E, Trivelli A, Picca S, et al. ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. *N Engl J Med*. 2009; 361(17): 1639–1650, doi: [10.1056/NEJMoa0902066](https://doi.org/10.1056/NEJMoa0902066), indexed in Pubmed: [19846849](https://pubmed.ncbi.nlm.nih.gov/19846849/).
248. Wühl E, Witte K, Soergel M, et al. German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. *J Hypertens*. 2002; 20(10): 1995–2007, indexed in Pubmed: [12359978](https://pubmed.ncbi.nlm.nih.gov/12359978/).
249. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet*. 2016; 387(10017): 435–443, doi: [10.1016/S0140-6736\(15\)00805-3](https://doi.org/10.1016/S0140-6736(15)00805-3), indexed in Pubmed: [26559744](https://pubmed.ncbi.nlm.nih.gov/26559744/).
250. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. *JAMA*. 2012; 307(12): 1273–1283, doi: [10.1001/jama.2012.339](https://doi.org/10.1001/jama.2012.339), indexed in Pubmed: [22427615](https://pubmed.ncbi.nlm.nih.gov/22427615/).
251. Yusuf S, Diener HC, Sacco RL, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med*. 2008; 359(12): 1225–1237, doi: [10.1056/NEJMoa0804593](https://doi.org/10.1056/NEJMoa0804593), indexed in Pubmed: [18753639](https://pubmed.ncbi.nlm.nih.gov/18753639/).
252. Yusuf S, Sleight P, Pogue J, et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000; 342(3):

145–153, doi: [10.1056/NEJM200001203420301](https://doi.org/10.1056/NEJM200001203420301), indexed in Pubmed: [10639539](https://pubmed.ncbi.nlm.nih.gov/10639539/).

253. Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet*. 2008; 372(9644): 1174–1183, doi: [10.1016/S0140-6736\(08\)61242-8](https://doi.org/10.1016/S0140-6736(08)61242-8), indexed in Pubmed: [18757085](https://pubmed.ncbi.nlm.nih.gov/18757085/).

254. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008; 358(15): 1547–1559, doi: [10.1056/NEJMoa0801317](https://doi.org/10.1056/NEJMoa0801317), indexed in Pubmed: [18378520](https://pubmed.ncbi.nlm.nih.gov/18378520/).

255. Zalecenia Kliniczne Polskiego Towarzystwa Diabetologicznego 2015. *Diabetologia Kliniczna*. 2015; 4(Supl. A): 42–47.

256. Zasady postępowania w nadciśnieniu tętniczym — 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. *Nadciśnienie Tętnicze*. 2011; 15: 55–82.

257. Zasady postępowania w nadciśnieniu tętniczym. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. *Nadciśnienie Tętnicze*. 2008; 12(5): 317–342.

258. Zimmet P, Alberti KG, Kaufman F, et al. IDF Consensus Group. The metabolic syndrome in children and adolescents — an IDF consensus report. *Pediatr Diabetes*. 2007; 8(5): 299–306, doi: [10.1111/j.1399-5448.2007.00271.x](https://doi.org/10.1111/j.1399-5448.2007.00271.x), indexed in Pubmed: [17850473](https://pubmed.ncbi.nlm.nih.gov/17850473/).

259. Zubrow AB, Hulman S, Kushner H, et al. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. *J Perinatol*. 1995; 15(6): 470–479, indexed in Pubmed: [8648456](https://pubmed.ncbi.nlm.nih.gov/8648456/).

